brain tumor
Conditions
Interventions
FACBC PET/CT
Sponsors
Tateishi Ukihide
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Patients with a history of radiotherapy and/or chemotherapy for brain tumors (regardless of the presence or absence of surgical history). 2.Patients suspected of recurrence on MRI (e.g., newly appearing or enlarging abnormal signal areas on MRI). 3.Patients aged 18 to 90 years at the time of obtaining informed consent. 4.Patients who have provided written informed consent to participate in this study.
Exclusion criteria
Exclusion criteria: 1.Patients with a known hypersensitivity to amino acids. 2.Patients with severe renal impairment (eGFR <30 mL/min/1.73 m2). 3.Pregnant patients, patients who may be pregnant, or patients (or their partners) who wish to become pregnant. 4.Breastfeeding patients. 5.Patients who are considered unable to provide appropriate consent due to mental or legal reasons. 6.Patients who are judged by the principal investigator or sub-investigators to be inappropriate for participation in this study for any other reason.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Diagnostic accuracy of FACBC PET/CT for detecting brain tumor recurrence, using pathological diagnosis or clinical diagnosis as the reference standard. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.Specificity 2.Sensitivity 3.Negative Predictive Value (NPV) 4.Positive Predictive Value (PPV) 5.Overall Survival (OS) Percentage of adverse events | — |
Contacts
Public ContactKota Yokoyama
Institute of Science Tokyo Hospital
Outcome results
None listed